Antepartum Monitors Market: Growth, Telehealth, and Hidden Barriers

Why is the antepartum monitors market growing?

The antepartum monitors market is expanding because of rising demand for high-risk pregnancy care and the adoption of telehealth. According to The Business Research Company, the market for AI-enhanced antenatal remote monitoring grew from $1.47 billion in 2025 to $1.73 billion in 2026, representing a compound annual growth rate of 17.5%.

This growth is expected to continue through 2035. The Business Research Company forecasts that the AI-enhanced segment will reach $3.32 billion by 2030, with a compound annual growth rate of 17.7%.

How do AI-enhanced monitoring systems work?

AI-enhanced antenatal remote monitoring systems use digital health solutions to track maternal and fetal health remotely. These tools aim to identify pregnancy-related complications early and provide continuous, personalized prenatal care.

The market includes a mix of software, hardware, and services. These technologies are used by hospitals, clinics, homecare settings, and diagnostic centers for applications such as high-risk pregnancy management, routine prenatal care, and fetal monitoring.

Where is the market expanding fastest?

North America holds the largest market share for AI-enhanced antenatal remote monitoring. Meanwhile, the Asia-Pacific region is identified as the fastest-growing market for these technologies.

Can remote monitoring solve the maternal mortality crisis?

CDC data show that more than 80% of pregnancy-related deaths in the United States are preventable. CDC data show that 53% of pregnancy-related deaths occur between one week and one year after delivery. Hypertensive disorders, which affect up to 10% of pregnancies, can persist or first appear during this postpartum period.

As many as 40% of women miss the postpartum visit entirely. An AHRQ-commissioned systematic review found that home monitoring doubled the likelihood of a blood pressure reading in the first 10 days after birth and reduced racial disparities in ascertainment by about half.

At UChicago Medicine, integrating telehealth and remote patient monitoring into a protocol bundle increased attendance at the first postpartum blood pressure check from 33.5% to 84.0%. A program at Novant Health for rural and underserved patients reported 0% readmissions for those using remote monitoring, compared to 5% for matched controls.

What are the clinical benefits for high-risk pregnancies?

A meta-analysis of 32 randomized trials found that telemedicine for gestational diabetes lowered HbA1c levels and reduced the rates of cesarean deliveries, neonatal hypoglycemia, and macrosomia.

The CONCEPTT trial showed that continuous glucose monitoring improved neonatal outcomes for patients with type 1 diabetes. However, evidence for other conditions is less certain, as the BUMP trials found that home self-monitoring of blood pressure during pregnancy yielded mixed results.

What are the hidden costs and barriers to adoption?

While the global intrapartum monitoring devices market is projected to grow from $1.78 billion in 2025 to $2.81 billion by 2031 at a compound annual growth rate of 7.91%, significant systemic challenges remain. The industry is driven by a rising global incidence of high-risk pregnancies and the need for non-invasive, wireless monitoring systems to help lower maternal and neonatal mortality. Koninklijke Philips N.V. reported a 7% increase in comparable sales for its Connected Care business in the fourth quarter of 2024, reflecting this demand for patient monitoring technology.

Data from 2026 shows that more than 35% of U.S. counties are classified as maternity care deserts, and more than 57% of rural hospitals no longer provide labor and delivery services. These gaps are particularly problematic given that the national preterm birth rate in the United States was 10.4% in 2025, with approximately 380,000 preterm births recorded in 2024. The primary cesarean delivery rate in the U.S. climbed to 22.9% in 2024.

Adoption of advanced monitoring tools is further restricted by economic and regulatory hurdles. The market faces delays due to stringent regulatory frameworks that slow the approval of new devices. The high cost of these systems limits their implementation in lower-income healthcare settings, where they are often needed most. If you are evaluating these technologies for your facility, you must account for these regulatory timelines and the upfront capital expenditures required to integrate them into your existing care infrastructure.